Can These Stocks Bounce Back? Threshold Pharmaceuticals Inc (THLD), Sangamo Biosciences Inc (SGMO) and ImmunoCellular Therapeutics Ltd (IMUC)

Posted by admin March 26, 2015 0 Comment 851 views


New York, NY – GDP INSIDER  –  03/26/2015.

This article discusses three companies: Threshold Pharmaceuticals Inc (NASDAQ:THLD), Sangamo Biosciences Inc (NASDAQ:SGMO) and ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)

Threshold Pharmaceuticals Inc (NASDAQ:THLD) continued to decline yesterday with the stock down 5.32% or $0.23 to close at $4.09 on active trading of 1.215 million shares, compared to its three month average trading volume of 0.652 million. The biotechnology company specialized in developing treatments for tumors has been fluctuating between $4.09 and $4.62 for the last month, with an overall downward trend but even so, the stock has still gained 34.53% for the year so far. With a one year target estimate of $12.90 the stock is worth holding on to for now.

Is Threshold Pharmaceuticals Inc Current Trend Going To Reverse? Delve Into The Financials With Free THLD Analysis.

Sangamo Biosciences Inc (NASDAQ:SGMO) corrected further yesterday from its 52 week high of $20.12 on Friday, with the stock closing down 9.07% or $1.50 at $15.03 with more than 1.472 million shares changing hands, compared to its three month average trading volume of 0.944 million. The clinical stage biopharmaceutical company focused on DNA binding proteins has been outperforming the S&P 500 for the last six weeks, but is now down 1.17% YTD, compared to the S&P 500 which increased 0.10% over the same period. With RSI of 39.37 it is a hold and potential buy if it falls lower.

Is Sangamo Biosciences Inc Undervalued? Take A Look At The Technical Indicators With Free SGMO Analysis.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) continued its steady decline yesterday with the stock losing another 4.56% or $0.025 to close at $0.5250 on active trading of 1.449 million shares, compared to its three month average trading volume of 0.687 million. ImmunoCellular Therapeutics Ltd been losing value since the beginning of the year and is now down 28.07% YTD. The developer of immune based therapies for brain and other cancers is also approaching a bearish MACD crossover and may continue to fall in the near term, making it a sell at the moment.

Do ImmunoCellular Therapeutics Ltd Fundamentals Support Its Current Value? Click Here For Free IMUC Analysis.

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment